FLNA Stock Chart & Stats
$15.92
$0.00(0.00%)
At close: 4:00 PM EDT
$15.92
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$13.12 - $86.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$650.61M
Enterprise Value-$25.19
Total Cash (Recent Filing)$82.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,307,896
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$84.50Price Target Upside430.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageNear-zero debt limits interest obligations and reduces leverage pressure during the development stage. This gives Filana greater financial flexibility than a similarly loss-making biotech with substantial borrowings, although it does not remove the need to fund operations.
Improved Cash-burn RateThe substantial reduction in operating cash burn during 2025 is a constructive efficiency trend, potentially extending available funding. Because cash flow remains negative, the improvement is supportive rather than evidence of self-sustaining operations or durable cash generation.
Board And Governance ContinuityShareholder approval of the board, auditor, and compensation framework supports continuity in oversight and execution during a development-stage period. Stable governance can help maintain strategic focus, though the event does not itself change the company’s financial trajectory.
Bears Say
No Revenue BasePersistent zero revenue confirms that Filana remains dependent on development progress, future commercialization, or partnering to establish an operating business. Without recurring sales, revenue visibility is weak and financial outcomes remain highly sensitive to clinical and strategic execution.
Persistent Operating LossesRecurring losses, including a sharp deterioration in 2025, demonstrate that current operations do not yet support profitability. Continued losses can consume capital and make future earnings power dependent on successful commercialization, partnering, or changes in spending.
Eroding Equity And Asset BaseThe sustained decline in equity and total assets reflects cumulative capital consumption and reduces financial flexibility. Combined with ongoing losses and no revenue, this deterioration increases the likelihood that additional capital will be needed to sustain development activities.
Filana Therapeutics News
FLNA FAQ
What was Filana Therapeutics’s price range in the past 12 months?
Filana Therapeutics lowest stock price was $13.12 and its highest was $86.00 in the past 12 months.
What is Filana Therapeutics’s market cap?
Filana Therapeutics’s market cap is $650.61M.
When is Filana Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Filana Therapeutics’s earnings last quarter?
Currently, no data Available
Is Filana Therapeutics overvalued?
According to Wall Street analysts Filana Therapeutics’s price is currently Undervalued.
Does Filana Therapeutics pay dividends?
Filana Therapeutics does not currently pay dividends.
What is Filana Therapeutics’s EPS estimate?
Filana Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Filana Therapeutics have?
Filana Therapeutics has 48,307,896 shares outstanding.
What happened to Filana Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Filana Therapeutics?
Currently, no hedge funds are holding shares in MX:FLNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Filana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Filana Therapeutics
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
FLNA Stock 12 Month Forecast
Average Price Target
$84.50
▲(430.77% Upside)